VOLITIONRX LTD — Director's Dealing 2017

Feb 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2017-02-14

Reporting Person: TERRELL JASON BRADLEY MD (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-14	Warrant (Right to Buy)	$2.47	D	25000	Disposed		Common Stock (25000)	Direct
2017-02-14	Warrant (Right to Buy)	$2.47	A	25000	Acquired		Common Stock (25000)	Direct

Footnotes

F1: The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The replacement warrant amends the performance criteria for a vesting milestone.

F2: The date exercisable is variable and depends on the achievement of the performance criteria outlined in the warrant agreement, as amended.

F3: The subject warrant shall expire three years after the vesting date.